Previous Close | 42.64 |
Open | 42.35 |
Bid | 0.00 x 48300 |
Ask | 0.00 x 51100 |
Day's Range | 42.35 - 43.10 |
52 Week Range | 39.94 - 49.37 |
Volume | |
Avg. Volume | 425,914 |
Market Cap | 9.822B |
Beta (5Y Monthly) | 0.38 |
PE Ratio (TTM) | 33.48 |
EPS (TTM) | 1.27 |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | Jan 25, 2017 |
1y Target Est | 47.90 |
VENLO, The Netherlands, March 13, 2023--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has filed its annual report, including its audited consolidated financial statements on Form 20-F, for the year ended December 31, 2022, with the U.S. Securities and Exchange Commission. The document can be accessed on QIAGEN’s website here.
QIAGEN (QGEN) will develop a real-time in vitro PCR test that can be utilized to spot IDH1 gene mutations in AML patients in whole blood and bone marrow aspirates.
VENLO, the Netherlands, March 09, 2023--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced it has entered into a strategic partnership with Servier, a global pharmaceutical group, to develop a companion diagnostic test for TIBSOVO®, an isocitrate dehydrogenase-1 (IDH1) inhibitor indicated for the treatment of the blood cancer acute myeloid leukemia (AML).